ABBOTT'S BREAKTHROUGH DISSOLVING STENT RECEIVES FDA APPROVAL FOR ARTERIES BELOW THE KNEE

Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is ...

Related Keywords

San Francisco ,California ,United States ,Alicia Swanson ,Sahila Parikh ,Endovascular Revascularization ,Mike Comilla ,Julie Tyler ,Columbia University Irving Medical Center ,Drug Administration ,Eluting Resorbable Scaffold ,Eluting Resorbable Scaffold System ,Transcatheter Cardiovascular Therapeutics ,New England Journal ,Vasc Surg ,Knee Endovascular Revascularization ,Abbott Media ,Abbott Financial ,